Molecular Construction Method Allows Synthesis of Valuable Chiral Drugs

    A new technique for constructing chiral drug molecules, whose structural complexity allows them to have mirror-image, “left-handed” and “right-handed” forms, has been developed at The Scripps Research Institute (TSRI). Unlike most previous chirality-inducing reactions, the novel method requires only starting chemicals that are inexpensive and widely available.

Medicilon’s drug discovery platform serves the early stages of new drug research and development projects, and is committed to helping customers obtain pharmaceutical substitute compounds through high-quality and efficient chemical and biological research services. Medicilon utilizes asymmetric synthesis technology, chiral decomposition and chiral separation technology to improve the efficiency of chiral drug research and development, which has advanced the chiral drugs of many leading pharmaceutical company to the next stage. 

    The new molecular construction method, unveiled in a Science online First Release paper (“Formation of α-Chiral Centers by Asymmetric β-C(sp³)–H Arylation, Alkenylation, and Alkynylation”), reportedly represents a significant milestone in chiral chemistry. It creates a structure that chemists call an α-chiral center, thereby enabling the synthesis of a great variety of potentially valuable chiral drugs and other products.

    At the same time, unlike most previous chirality inducing reactions, it requires only inexpensive and widely available starting chemicals, according to its inventors.

    “This method essentially mimics the ability of the enzymes in our cells to turn simple organic molecules into chiral molecules,” said senior author Jin-Quan Yu, Ph.D., Frank and Bertha Hupp Professor in the department of chemistry at TSRI.

    Over the past decade or so, Dr. Yu and his laboratory have invented a number of new molecule-building reactions that have been adopted by chemists in academia and industry. Most are C–H activation reactions, which remove a hydrogen atom from one of the carbon atoms of the molecular backbone and replace it with a more complex cluster of atoms called a functional group. Increasingly, Dr. Yu and his colleagues have designed these reactions to create the asymmetry needed for chiral drugs.

    In a paper in Science last August, for example, they described a set of chiral asymmetry-making reactions that work by selectively activating just one of the two hydrogen atoms on a methylene group (CH₂), a feature of many organic molecules. Like most of the C–H activations developed by the Yu laboratory, this reaction employs a palladium atom to break the targeted C–H bond and a special ligand molecule to steer the palladium atom precisely where it needs to go.

    The new set of reactions has an even more challenging target: a cluster of carbon and hydrogen atoms known as an isopropyl group, another feature of many organic molecules. The ligands developed for the reaction, derivatives of aminomethyl oxazoline, effectively select a carbon at just one side of the isopropyl group and replace one of its hydrogen atoms with a functional group.

    Dr. Yu’s team showed that they can use the ligands to add aryl, alkene, and alkyne functional groups, common building blocks in the construction of drug molecules.

    The intended starting material for the new reactions is the bis(isopropyl)-bearing molecule isobutyric acid, although the reactions also work well on related molecules. Isobutyric acid is cheaply produced in very large quantities using standard industrial methods, and it can also can be generated from waste biomass, such as crushed sugar cane, making it a more environmentally friendly ingredient for chemical reactions.

    Isobutyric acid is also found in nature, and bacteria and other organisms have evolved enzymes that convert it to natural chiral molecules. In the past few decades, pharmaceutical chemists have learned to harness some of these natural enzyme reactions—using genetically engineered bacteria—to help them build chiral drug molecules. However, these enzyme-driven reactions are restricted to isobutyric acid as a starting molecule and are very limited in the chiral molecules they can yield. The new ligand/catalyst, while essentially mimicking nature’s synthetic feat, is much more versatile.

    “Now that we know how to selectively break that one C–H bond with a palladium catalyst, we’re not limited to the reactions that enzymes can do,” Dr. Yu said.

    He added that researchers at Bristol-Myers Squibb, which has a research collaboration agreement with the Yu laboratory, are already using the new reactions to make potential new drug molecules.